Biogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.
https://www.pharmalive.com/wp-content/uploads/2020/07/Biogen-to-study-Spinraza-in-combination-with-2-million-Novartis-drug-Reuters-7-21-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2020-11-27 12:36:382020-11-30 15:47:01Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics